Rekombinanter PDCD1 (Spartalizumab Biosimilar) Antikörper

Produktnummer ABIN7200669

Der Humanized Monoklonal Anti-PDCD1 (Spartalizumab Biosimilar) Antikörper wurde für FACS und in vivo validiert. Er ist geeignet, PDCD1 (Spartalizumab Biosimilar) in Proben von Human zu detektieren.

Kurzübersicht für Rekombinanter PDCD1 (Spartalizumab Biosimilar) Antikörper (ABIN7200669)

Target: PDCD1 (Spartalizumab Biosimilar)

Antikörpertyp: Recombinant Antibody

Reaktivität: Human

Wirt: Humanized

Klonalität: Monoklonal

Konjugat: Dieser PDCD1 (Spartalizumab Biosimilar) Antikörper ist unkonjugiert

Applikation: Flow Cytometry (FACS), In vivo Studies (in vivo)

Güteklasse: Research Grade

Produktdetails anti-PDCD1 (Spartalizumab Biosimilar) Antikörper

Verwendungszweck: Spartalizumab Biosimilar, Human PD-1 Monoclonal Antibody

Spezifität: The in vivo grade spartalizumab biosimilar specifically binds to the programmed cell death protein 1 (PD-1), antagonizing its interaction with its known ligands PD-L1 and PD-L2.

Produktmerkmale: Spartalizumab Biosimilar uses the same protein sequences as the therapeutic antibody spartalizumab. A humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1), with immune checkpoint inhibitory and antineoplastic activities. Upon administration, spartalizumab binds to PD-1 expressed on activated T cells and blocks the interaction with its ligands, programmed cell death 1 ligand 1 (PD-L1, PD-1L1) and PD-1 ligand 2 (PD-L2, PD-1L2). The inhibition of ligand binding prevents PD-1-mediated signaling and results in both T-cell activation and the induction of T-cell-mediated immune responses against tumor cells. PD-1, an immunoglobulin (Ig) superfamily transmembrane protein and inhibitory receptor, negatively regulates T-cell activation.

Aufreinigung: Protein A or G affinity column

Reinheit: >95 % by reducing SDS-PAGE

Sterilität: 0.2 μm filtered

Endotoxin-Niveau: < 1 EU per 1 mg of the protein by the LAL method

Immunogen: The anti-human PD-1 monoclonal antibody spartalizumab biosimilar was produced in mammalian cells.

Isotyp: IgG1

Anwendungsinformationen

Applikationshinweise: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by spartalizumab.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: > 3 mg/mL

Buffer: PBS, pH 7.4, no stabilizers or preservatives.

Konservierungsmittel: Without preservative

Lagerung: 4°C,-20 °C

Informationen zur Lagerung: 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.

Haltbarkeit: 12 months

Details zu PDCD1 (Spartalizumab Biosimilar)

Target: PDCD1 (Spartalizumab Biosimilar)

Andere Bezeichnung: Spartalizumab Biosimilar

Substanzklasse: Biosimilar